Nexalin Technology (NXL) Return on Capital Employed (2022 - 2026)
Nexalin Technology (NXL) recorded quarterly Return on Capital Employed of 253.22% in Q1 2026, down 20.51% quarter-over-quarter from 210.12% in Q4 2025, and up 3781.0% on a YoY basis from 6.52% in Q1 2025.
Nexalin Technology (NXL) Return on Capital Employed (2022 - 2026) Analysis & Trends
Nexalin Technology's Return on Capital Employed history runs 5 years deep, the most recent figure standing at 253.22% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 3781.0% year-over-year to 253.22%; the TTM figure through Mar 2026 stood at 253.22% (up 3781.0% YoY), while the FY2025 annual figure was 236.92%, down 753.0% from the prior year.
- Return on Capital Employed was 253.22% for Q1 2026 at Nexalin Technology, down from 210.12% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 30.84% in Q4 2022 to a low of 322.71% in Q2 2024.
- Historically, Return on Capital Employed has averaged 178.13% across 5 years, with a median of 197.0% in 2024.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed tumbled 26163 bps in 2024, then surged 10448 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 30.84% in 2022, then sank by 412 bps to 157.9% in 2023, then fell by 17 bps to 184.93% in 2024, then slipped by 14 bps to 210.12% in 2025, then declined by 21 bps to 253.22% in 2026.
- The last three Return on Capital Employed figures came in at 253.22% (Q1 2026), 210.12% (Q4 2025), and 161.33% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 9.61% |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 12.24% |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 7.36% |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 9.62% |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 11.13% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 10.45% |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 24.24% |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 9.30% |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 11.57% |
| 10 | Nexalin Technology | 7.82 Mn | 5.11 Mn | 13,133.00 | -253.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -253.22% |
| Dec 31, 2025 | -210.12% |
| Sep 30, 2025 | -161.33% |
| Jun 30, 2025 | -218.23% |
| Mar 31, 2025 | -291.03% |
| Dec 31, 2024 | -184.93% |
| Sep 30, 2024 | -209.07% |
| Jun 30, 2024 | -322.71% |
| Mar 31, 2024 | -219.77% |
| Dec 31, 2023 | -157.90% |
| Sep 30, 2023 | -132.81% |
| Jun 30, 2023 | -61.07% |
| Mar 31, 2023 | -40.78% |
| Dec 31, 2022 | -30.84% |